6:46AM Pharmasset receives fast track designation from the FDA for the treatment of chronic hepatitis C infection (VRUS) 125.21 : Pharmasset plans to initiate QUANTUM, an interferon-free combination trial with PSI-938 and PSI-7977 in the third quarter of 2011.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.